220 related articles for article (PubMed ID: 12544532)
1. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
Kram MT; May LD; Goodman S; Molinas S
Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.
Hassard PV; Binder SW; Nelson V; Vasiliauskas EA
Gastroenterology; 2001 Mar; 120(4):995-9. PubMed ID: 11231954
[TBL] [Abstract][Full Text] [Related]
3. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
4. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Park J; Cheon JH
Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
[TBL] [Abstract][Full Text] [Related]
5. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
[TBL] [Abstract][Full Text] [Related]
6. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR
Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
[TBL] [Abstract][Full Text] [Related]
7. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
9. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease.
Nakamura S; Ohno S
Int Ophthalmol Clin; 2005; 45(2):179-89. PubMed ID: 15791165
[No Abstract] [Full Text] [Related]
12. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
13. An incomplete form of childhood Behçet's disease treated with infliximab.
Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M
Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037
[TBL] [Abstract][Full Text] [Related]
14. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.
Almoznino G; Ben-Chetrit E
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S99-102. PubMed ID: 17949561
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.
Lee JH; Cheon JH; Jeon SW; Ye BD; Yang SK; Kim YH; Lee KM; Im JP; Kim JS; Lee CK; Kim HJ; Kim EY; Kim KO; Jang BI; Kim WH
Inflamm Bowel Dis; 2013 Aug; 19(9):1833-8. PubMed ID: 23702810
[TBL] [Abstract][Full Text] [Related]
16. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary artery aneurysms in Behçet's disease treated with anti-TNFα: A case series and review of the literature.
Chan E; Sangle SR; Coghlan JG; D'Cruz DD
Autoimmun Rev; 2016 Apr; 15(4):375-8. PubMed ID: 26777307
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment.
Sari I; Birlik M; Gonen C; Akar S; Gurel D; Onen F; Akkoc N
World J Gastroenterol; 2008 May; 14(18):2912-4. PubMed ID: 18473420
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis triggered by infliximab in a patient with Behçet's disease.
Kawazoe Y; Sugita S; Yamada Y; Akino A; Miura K; Mochizuki M
Jpn J Ophthalmol; 2013 Jan; 57(1):95-7. PubMed ID: 23090423
[TBL] [Abstract][Full Text] [Related]
20. Local injection of infliximab in symptomatic isolated mucosal lesions: a novel scenario for endoscopic therapy?
Lorenzo-Zúñiga V; Boix J; Mañosa M; Lezcano C; Cabré E; Moreno de Vega V; Domènech E
Inflamm Bowel Dis; 2013; 19(4):E59-61. PubMed ID: 22605623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
